Many N,N-dialkylated tryptamines show psychoactive properties and were encountered as new psychoactive substances. The aims of the presented work were to study the phase I and II metabolism and the detectability in standard urine screening approaches (SUSA) of 5-methoxy-2-methyl-N,N-diallyltryptamine (5-MeO-2-Me-DALT), 5-methoxy-2-methyl-N-allyl-Ncyclohexyltryptamine (5-MeO-2-Me-ALCHT), and 5-methoxy-2-methyl-N,N-diisopropyltryptamine (5-MeO-2-Me-DIPT) using gas chromatography-mass spectrometry (GC-MS), liquid chromatography coupled with multistage accurate mass spectrometry (LC-MS n ), and liquid chromatography-high-resolution tandem mass spectrometry (LC-HR-MS/MS). For metabolism studies, urine was collected over a 24 h period after administration of the compounds to male Wistar rats at 20 mg/kg body weight (BW). Phase I and II metabolites were identified after urine precipitation with acetonitrile by LC-HR-MS/MS. 5-MeO-2-Me-DALT (24 phase I and 12 phase II metabolites), 5-MeO-2-Me-ALCHT (24 phase I and 14 phase II metabolites), and 5-MeO-2-Me-DIPT (20 phase I and 11 phase II metabolites) were mainly metabolized by O-demethylation, hydroxylation, N-dealkylation, and combinations of them as well as by glucuronidation and sulfation of phase I metabolites. Incubations with mixtures of pooled human liver microsomes and cytosols (pHLM and pHLC) confirmed that the main metabolic reactions in humans and rats might be identical. Furthermore, initial CYP activity screenings revealed that CYP1A2, CYP2C19, CYP2D6, and CYP3A4 were involved in hydroxylation, CYP2C19 and CYP2D6 in O-demethylation, and CYP2C19, CYP2D6, and CYP3A4 in N-dealkylation. For SUSAs, GC-MS, LC-MS n , and LC-HR-MS/MS were applied to rat urine samples after 1 or 0.1 mg/kg BW doses, respectively. In contrast to the GC-MS SUSA, both LC-MS SUSAs were able to detect an intake of 5-MeO-2-Me-ALCHT and 5-MeO-2-Me-DIPT via their metabolites following 1 mg/kg BW administrations and 5-MeO-2-Me-DALT following 0.1 mg/kg BW dosage.
Introduction
New psychoactive substances (NPS) have become increasingly popular among drug users around the world. [1] As many of them are not regulated, these substances are marketed to avoid criminal prosecution for production, trading, drug possession, or consumption. NPS often mimic the effects of their traditional counterparts. [1] Several hundred substances are classified as NPS where research on the potential harm for consumers is limited. Synthetic cannabinoids, phenylethylamines, synthetic cathinones, and tryptamines were the most prevalent representatives of NPS in the last few years. [1] The biological effects associated with many psychoactive tryptamine derivatives are at least in part mediated by agonism at 5-HT 1A and 5-HT 2A receptors leading to hallucinogenic and stimulating effects. [2] [3] [4] [5] [6] [7] The synthesis and mode of action for many synthetic tryptamines were described by Shulgin and Shulgin. [8] Examples of tryptamines describedby them and subsequently appeared in case reports include 5-MeO-MIPT (5-methoxy-N-methyl-N-isopropyltryptamine) [9] and 5-MeO-DIPT (5-methoxy-N,N-diisopropyltryptamine). [10] [11] [12] [13] [14] Other tryptamines, such as 5-MeO-DALT (5-methoxy-N,Ndiallyltryptamine), [15, 16] originally not described by Shulgin and Shulgin in 1997, [8] have also appeared on the market and were linked to intoxication cases. Shulgin and Shulgin [8] have also described the effects of tryptamines substituted on the 2-position of the indole ring such as 5-MeO-TMT (5-methoxy-2,N,Ntrimethyltryptamine). From this perspective, it seems conceivable that other 2-methylated tryptamines might also appear on the drug market. In cases of intoxication with such substances, it is necessary to provide analytical detection methods, such as standard urine screening approaches (SUSAs) [17] in order to facilitate adequate support of the therapeutic strategy used for clinical treatment. As shown by Michely et al., [18] tryptamines were mainly excreted as metabolites thus the targets for urine screening have to be elucidated by metabolism studies to include those in SUSAs. This work here is focused on the metabolism and the detectability of the three NPS 5-methoxy-2-methyl-N,Ndiallyltryptamine (5-MeO-2-Me-DALT), 5-methoxy-2-methyl-Nallyl-N-cyclohexyltryptamine (5-MeO-2-Me-ALCHT), and 5methoxy-2-methyl-N,N-diisopropyltryptamine (5-MeO-2-Me-DIPT), respectively.
Experimental
Chemicals and reagents 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT were available from previous studies and synthesized by Brandt et al. [19] [20] [21] Isocitrate, isocitrate dehydrogenase, and 3 0phosphoadenosine-5 0 -phosphosulfate (PAPS) were received from Sigma-Aldrich (Taufkirchen, Germany), NADP + from Biomol (Hamburg, Germany), and methanol (liquid chromatography-mass spectrometry (LC-MS) grade), ammonium formate (analytical grade), formic acid (LC-MS grade), and acetonitrile (LC-MS grade) and all other chemicals or reagents (analytical grade) from VWR (Darmstadt, Germany). The baculovirus-infected insect cell microsomes (supersomes) containing human cDNA-expressed cytochrome P450 (CYP) enzymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4 (1 nmol/mL, each), or CYP2E1, CYP3A5 (2 nmol/mL, each), pooled human liver microsomes (pHLM, 20 mg microsomal protein/mL, 330 pmol total CYP/mg protein), pooled human liver cytosols (pHLC, 20 mg cytosolic protein/mL), UDP-glucuronyltransferase (UGT) reaction mix solution A (25 mM UDP-glucuronic acid), and UGT reaction mix solution B (250 mM Tris-HCl, 40 mM MgCl 2 , and 0.125 mg/mL alamethicin) were obtained from Corning (Amsterdam, the Netherlands). After delivery, the enzyme preparations were thawed at 37°C, aliquoted, snap-frozen in liquid nitrogen, and stored at À80°C until use.
Urine samples
The compounds were orally administered in an aqueous suspension by gastric intubation to male Wistar rats (Charles Rivers, Sulzfeld, Germany) for toxicological diagnostic reasons. [18] Doses were 20 mg/kg body weight (BW) for metabolism studies (identification of metabolites), 1 mg/kg BW for toxicological analyses, and 0.1 mg/kg BW for estimation of the detectability of very low dosed applications, respectively. After administration, the rats were housed in metabolism cages for 24 h. Water was provided ad libidum and urine collected separately from feces. Before administration, blank urine samples were collected to evaluate the absence of interfering compounds. Urine samples were extracted, analyzed, and stored at À20°C immediately after collection.
Sample preparation for identification of phase I and II metabolites by LC-HR-MS/MS
As described elsewhere, [22] 100 μL urine were mixed with 500 μL acetonitrile, vortexed for 2 min and centrifuged for further 2 min at 10 000 g. Five hundred μL of the supernatant were transferred into a glass vial and evaporated at 70°C under a stream of nitrogen. The residue was dissolved in 50 μL of a mixture (1:1; v/v) of eluents A (2 mM aqueous ammonium formate plus 0.1% formic acid, pH 3) and B (2 mM aqueous ammonium formate with acetonitrile: methanol, 50:50, v/v; 1% water plus 0.1% formic acid) and a 1-μL aliquot was injected onto the liquid chromatography-high resolution-tandem mass spectrometry (LC-HR-MS/MS) system.
Conditions for incubations for initial CYP activity screening studies
According to Richter et al., [23] The solution was then centrifuged for 5 min at 10 000 g, 70 μL of the supernatant were transferred to an autosampler vial, and 1 μL was injected onto the LC-HR-MS/MS system. Blank and negative control samples were also prepared accordingly, whereby substrate or enzymes were replaced with buffer, respectively.
Conditions for incubations with pHLM + pHLC
As described by Richter et al., [23] the in vitro drug metabolism studies using a mixture of pHLM and pHLC were done with final protein concentrations of 1 mg/mL each. After 10 min of preincubation at 37°C with 20 μL UGT reaction mix solution B, pHLM, pHLC, 90 mM phosphate buffer (pH 7.4), 2.5 mM Mg 2+ , 2.5 mM isocitrate, 0.6 mM NADP + , 0.8 U/mL isocitrate dehydrogenase, 100 U/mL superoxide dismutase, 10 μL UGT reaction mix A, and 40 μM aqueous PAPS were added. All given concentrations are final concentrations. The reaction was initiated by adding substrate at 25 μM (100 μL final volume) and stopped after 30 min incubation time with 50 μL ice-cold acetonitrile. The samples were centrifuged for 2 min at 10 000 g, 100 μL of the supernatant transferred into an autosampler vial, and 1 μL injected onto the LC-HR-MS/MS system. A blank and a negative control sample were also prepared, whereby substrate or enzyme was replaced with buffer, respectively.
the manufacturer's manual, mass calibration was done before analysis using external mass calibration. LC and MS settings were according to published procedures. [23, 24] The gradient elution was performed on a TF Accucore PhenylHexyl column (100 × 2.1 mm, 2.6 μm). Chromatographic separation was performed at 40°C supplied by an analytical column heater (Dionex UltiMate 3000). The gradient was programmed as follows: 0-1 min 99% A, 1-10 min to 1% A, 10-11.5 min hold 1% A, and 11.5-13.5 min hold 99% A. The flow rate was set to 500 μL/min for 10 min and 800 μL/min from 10 to 13.5 min. The HESI-II source conditions were as follows: sheath gas, 60 arbitrary units (AU); auxiliary gas, 10 AU; spray voltage, 3.00 kV; heater temperature, 320°C; ion transfer capillary temperature, 320°C; and S-lens RF level, 60.0. Mass spectrometry analyses were performed using full-scan (FS) data and a subsequent data dependent acquisition (DDA) mode with an inclusion list of the m/z values of 5- 
Standard urine screening approaches (SUSA)
The SUSAs were performed as described previously: GC-MS SUSA, [17, 25] LC-MS n SUSA, [26, 27] and LC-HR-MS/MS SUSA. [26, 28] Results and discussion
Identification of phase I and II metabolites via LC-HR-MS/MS
Mass spectral interpretations were based on general fragmentation rules [29] and by comparison with the spectra of the parent compounds. All phase I and II metabolites tentatively identified based on their MS 2 spectra are depicted in Figures S1-S6 in the Supporting Information (SI). Additionally, the spectra contain the supposed chemical structures, the accurate measured masses, the molecular formulae, and the corresponding mass error values in parts per million (ppm).
Proposed fragmentation patterns for identification of phase I metabolites via LC-HR-MS/MS
In general, all metabolites were identified based on their m/z values of the protonated molecule (PM), the calculated molecular formulae, and the fragmentation patterns compared to those of the parent compounds. They were sorted by PM and with abbreviations for the corresponding compound (5-MeO-2-Me-DALT, D; 5-MeO-2-Me-ALCHT, A; and 5-MeO-2-Me-DIPT, P). Due to the large number of metabolites detected in this study, only representative examples have been chosen to illustrate the fragmentation patterns. Following the suggestion described by Michely et al., [18] the chemical structures were divided into three sections to allow a convenient description of fragmentation patterns and positions of metabolic reactions. Section 1 represents the aromatic ring system, section 2 the ethyl spacer, and section 3 the variable amine part of the molecule. As expected, the fragment ions formed by sections 1 and 2 were the same for 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT. All masses in the following sections are the calculated (exact) masses.
5-MeO-2-Me-DALT
As shown in Figure S1 , 24 phase I metabolites of 5- Figure S1 ; PM at m/z 285.1961, C 18 H 25 ON 2 + ) showed a fragmentation comparable to DALT and 5-MeO-DALT [18] and for most of the detected metabolites. The fragment ions of m/z 188.1070 (C 12 ) could be observed and predicted to represent hydroxylated metabolites (D16-D20). Isomers 1-4 (D16-D19) showed fragment ions of m/z 110.0964 (C 7 H 12 N + ) indicating that the hydroxylation took place at sections 1 or 2. In the MS 2 spectrum of hydroxy-alkyl isomer 1 (D16), no specific shifts could be detected for the fragment ions (e.g. 188.1070 to 204.1019, +15.9949, +O) associated with sections 1 and 2 or any loss of water as in the MS 2 spectrum of hydroxy-alkyl isomer 2, which could indicate hydroxylation probably at the 2methyl group of section 1. The fragment ions of m/z 176.0706 (C 10 H 10 O 2 N + ) and 178.0863 (C 10 H 12 O 2 N + ) represented a hydroxylated methyl group in section 1 with the positive charge at the carbon or at the nitrogen atom, respectively. In contrast, the MS 2 spectra of the hydroxy-aryl isomers 1 and 2 (D17 and D18) showed typical shifts of +15.9949 u (+O) of the fragment ions of sections 1 and 2, thus, resulting in the fragment ions of m/z 189.0784 (C 11 H 11 O 2 N + ) and 204.1019 (C 12 H 14 O 2 N + ). Furthermore, there were no fragment ions associated with a loss of water in these two spectra and thus the two isomers were predicted to be aryl hydroxylated metabolites (D17 and D18). In contrast, the MS 2 spectrum of hydroxy-alkyl isomer 2 (D19) showed such a loss of water (À18.0106 u, H 2 O), typically observed with alkyl hydroxy groups, and therefore resulting in m/z 186.0913 (C 12 H 12 ON + ), which suggested that hydroxylation occurred in the ethylamine side chain in section 2. The MS 2 spectrum of isomer 5 (D20) showed neither presence of the fragment ion of unchanged section 3 (m/z 110.0964, (C 7 H 12 N + ), nor any typical shifts of this fragment ion. However, the fragment ions of unchanged sections 1 and 2 were detected and therefore the metabolite was inconsistent with a Metabolism of 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT Drug Testing and Analysis hydroxylated species. The presence of an N-oxide metabolite seemed likely as D20 had a longer retention time (5.0 min) than the parent compound (4.8 min) on the reversed phase column. This was observed for all N-oxides for which reference standards were available. [30] Figures S4 and S6 , 14 phase II metabolites of 5-MeO-2-Me-ALCHT and 11 of 5-MeO-2-Me-DIPT could be identified. As already described for 5-MeO-2-Me-DALT, all glucuronides and sulfates eliminated glucuronic acid (À176.0321 u) or sulfuric acid (À79.9568 u). In addition, conjugation always took place at the ethylindole part after O-demethylation or aryl-hydroxylation, forming the same fragment ions of the conjugated partial structure. As both compounds have some common phase I metabolites following N-dealkylation, the resulting phase II metabolites after further conjugation were consequently also identical (D6S, D8S, D4G, D6G, and D8G 2 for 5-MeO-2-Me-DALT; A6S, A9S, A4G, A6G, and A9G for 5-MeO-2-Me-ALCHT).
5-MeO

Proposed metabolic pathways
Based on the identified metabolites, the metabolic pathways for 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT were proposed and depicted in Figures 1-3 . The numbering is given in Figures S1, S3 , and S5. As expected, the main metabolic reactions observed for all three test drugs were comparable.
5-MeO-2-Me-DALT
Four different hydroxy isomers could be detected. Two isomers of hydroxy-aryl (D17 and D18) were formed by hydroxylation at the indole part. Hydroxy-alkyl isomer 1 (D16) led to further oxidation and/or hydroxylation steps in section 1 (D15, D21, D22, and D23). Hydroxylation at section 2, forming hydroxy-alkyl isomer 2 (D19), was probably the preliminary step for the formation of two N-deallyl-oxo isomers 1 and 2 (D7 and D8). Moreover, N-oxidation 
5-MeO-2-Me-ALCHT
The metabolic pathways were similar to those observed for 5-MeO-2-Me-DALT including N-oxidation (A23), aliphatic (A20 and A21), and aromatic (A22) hydroxylation. However, aliphatic hydroxylations did not affect section 2 but the 2-methyl substituent in section 1 and the cyclohexyl ring in section 3 instead. Combination of both hydroxylation types (aromatic and aliphatic) showed the bis-hydroxy metabolite (A25). An intermediate biotransformation step (aliphatic hydroxylation at the 2-methyl substituent) was originally considered, but this could not be identified, possibly due to fast oxidation to the carboxylic acid hydroxylations (A8 and A9), oxidation to amide structure (A7), O-demethylation (A4), combinations of both (A6), and further N-deallylation (A2), followed by oxidation to the corresponding carboxylic acid (A3). Retention times and MS 2 spectra of these metabolites were the same for 5-MeO-2-Me-DALT and -ALCHT. However, the alpha-position in metabolites A7 and D8 is not the probable position due to fact that the intermediate should be an unstable hemiaminal. The N-deallylated metabolite (A11) could be further metabolized by hydroxylation (A15 and A16), oxidation to an aldehyde (D14), O-demethylation (A10), and combination of O-demethylation with hydroxylation (A12 and A13). Glucuronidation and sulfation were found for O-demethyl-N-decyclohexyl-hydroxy-alkyl (A6), N-decyclohexyl (A8), O-demethyl-N-deallyl (A10), O-demethyl-N-deallyl-hydroxycyclohexyl (A12), O-demethyl (A17), and O-demethyl-hydroxycyclohexyl (A18) metabolites, whereas O-demethyl-N-decyclohexyl (A4) was only found as glucuronide. Two glucuronide isomers (A8G1 and A8G2) were detected for the N-decyclohexyl-hydroxyaryl metabolite (A8).
5-MeO-2-Me-DIPT
As expected, most 5-MeO-2-Me-DIPT metabolites were found to be equivalent to those described above, such as aliphatic (P15 and P18) and aromatic (P16 and P17) hydroxylations, combination of aliphatic and aromatic hydroxylation (P21), oxidation to an aldehyde (P14), and the corresponding carboxylic acid (P19), O-demethylation (P11), and N-deisopropylation (P5). The aldehyde metabolite (P14) could be further oxidized forming hydroxy-alkyloxo metabolite (P20). Furthermore, N,N-bis-deisopropylation (P2) and deamination to the corresponding carboxylic acid (P3) leading to the same metabolites as already seen for the DALT (D2 and D3) and ALCHT (A2 and A3) analogue. Combinations of N-deisopropylation with hydroxylations (P9 and P10) and O-demethylation (P6) as well as combinations of O-demethylation with hydroxylations (P12 and P13), and O-demethylation with N-deisopropylation (P4) were discovered. N-Deisopropylation in combination with oxidation to two oxo isomers (P7 and P8) could also be found as for the DALT analogue (D7 and D8). Glucuronidation and sulfation could be observed for O-demethyl-N-deisopropyl (P4) and O-demethyl (P11) metabolites. For O-demethyl-N-deisopropyl-hydroxy-alkyl (P6), N-deisopropylhydroxy-aryl (P9), O-demethyl-hydroxy-alkyl isomer 2 (P13), hydroxy-aryl isomer 1 and 2 (P16 and P17), and aryl-alkyl-bishydroxy (P21) metabolites, only glucuronides were found. Two glucuronide isomers (P9G1 and P9G2) were detected for the N-deisopropyl-hydroxy-aryl metabolite (P9).
Comparison to published 5-MeO-DALT and 5-MeO-DIPT metabolism studies
5-MeO-DALT
Michely et al. [18] described the metabolism of 5-MeO-DALT in rats. The main metabolic reactions (O-demethylation, hydroxylations, and N-deallylation) were similar for both compounds. However, some metabolites, especially those modified at the 2-methyl group could only be found for 5-MeO-2-Me-DALT. Compared to 5-MeO-DALT, no bis-or tris-hydroxylations and no ring-rearranged metabolite could be found for the 2-methyl derivative probably due to the substitution of the 2 position of the indole ring which could lead to a steric hindrance for the rearrangement. In addition, N,N-bis-deallylation followed by oxidative deamination and N-oxidation could only be detected for 5-MeO-2-Me-DALT.
5-MeO-DIPT
Narimatsu et al. [31] [32] [33] described, besides CYP kinetic studies, only the presence of a O-demethylated, a N-deisopropylated, and a mono-hydroxylated metabolite in rat and human liver microsomes, which all were also found in our study for 5-MeO-2-Me-DIPT.
Initial CYP activity screening studies
The ten most abundant human hepatic CYPs were incubated as described above to provide a qualitative description of metabolizing isoenzymes. As shown in Table 1 , the involved isoenzymes were the same for the three NPS. O-Demethylation was catalyzed by CYP2C19 and CYP2D6, N-deallylation, or N-deisopropylation by CYP2C19, CYP2D6, and CYP3A4, and hydroxylations by CYP1A2, CYP2C19, CYP2D6, and CYP3A4. Additionally, the N-decyclohexylation of 5-MeO-2-Me-ALCHT was catalyzed by CYP2C9, CYP2C19, and CYP3A4.
Incubations with pHLM and pHLC
Due to the lack of authentic human urine samples, in vitro testing was performed to evaluate the transferability of rat metabolism results to 
humans. The combination of rat urine studies and the incubation of pHLM and/or pHLC with the corresponding cofactors is a common technique that produced reliable results and data for detection methods in human urine as shown in previous studies. [23, [34] [35] [36] [37] However, it should be kept in mind, that the comparison of in vitro and in vivo models could be challenging due to sampling time of urine (24 h), time, amount, and route of application, the used incubation conditions, and/or genetic variations.
5-MeO-2-Me-DALT
As summarized in Table 2 , 22 out of 24 identified phase I metabolites of 5-MeO-2-Me-DALT were detected in rat urine, 14 could be confirmed in the in vitro approach. In addition, two hydroxy-alkyl metabolites (D16 and D19) were only detected in the in vitro model. This was probably based on the 24 h urine collection period and consequently further metabolism steps to the corresponding oxo or carboxy metabolites occurred in rat. D4, D6, D9, D11, D13, D17, and D18 were found as glucuronides, and D4, D6, D9, D11, and D18 as sulfates in vivo. D11, D17, and D18 were found as glucuronides and D18 as sulfate in vitro. These differences could have been based on the incubation time and lower formation of the corresponding phase I metabolites, especially in cases where multiple metabolic reaction steps were needed.
5-MeO-2-Me-ALCHT
As shown in Table 3 
in rat urine and one glucuronide under in vitro conditions. The reasons for these differences were considered comparable to those mentioned above. In comparison to 5-MeO-2-Me-DALT, no additional metabolites could be found in the in vitro model when compared to the in vivo approach.
5-MeO-2-Me-DIPT
According to Table 4 , 15 out of 20 phase I metabolites identified in vivo could also be found in the in vitro model. Nine glucuronides and two sulfates were identified in vivo, whereas two glucuronides were detected in vitro.
Toxicological detection by standard urine screening approaches (SUSAs)
So far, no data about dosages or potency of the compounds are available. Therefore, the tested dosages for 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT were estimated based on those described for other tryptamine-derived NPS and were set to 1 mg/kg BW and 0.1 mg/kg BW. Michely et al. [18] showed that such dosages were at or below common users doses of DALT and 5-MeO-DALT. The fact that the 0.1 mg/kg BW dosage was not detectable (except of 5-MeO-2-Me-DALT) could lead to a false negative result e.g. in context of forensic issues.
GC-MS SUSA
Unfortunately, the three compounds and/or their metabolites could not be detected in rat urine after low dosages probably due to low concentration or instabilities caused by the sample preparation. However, after high dose administration, some metabolites were detected, indicating 
LC-MS n SUSA
A list of all detected metabolites is given in Tables 5 and 6 . 5-MeO-2-Me-DALT was detectable via its metabolites after both low dose administrations. For 5-MeO-2-Me-ALCHT as well as 5-MeO-2-Me-DIPT, only metabolites were detectable after 1 mg/kg BW dosages, but not after the lower 0.1 mg/kg BW dosages.
LC-HR-MS/MS SUSA
As summarized in Table 7 , metabolites of 5-MeO-2-Me-DALT and 5-MeO-2-Me-DIPT could be identified with the accurate PM and a HR-MS/MS spectrum (identification, I) after 1 mg/kg BW dose administrations. In addition, metabolites could be identified after the lower 0.1 mg/kg BW dosage for 5-MeO-2-Me-DALT. For 5-MeO-2-Me-ALCHT, only detection (D) of the accurate PM without the corresponding HR-MS/MS spectrum was possible. A second run with an inclusion list on the masses of described metabolites would be necessary to confirm an intake of 5-MeO-2-Me-ALCHT. The parent compounds were not identified, nor have they been detected in any of the urine samples. Exemplified for 5-MeO-2-Me-DALT, Figure 4 shows a reconstituted ion chromatogram of the 1 mg/kg BW dosage rat urine sample with various detected metabolites.
Conclusions 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT were extensively metabolized in rats. In vitro metabolism studies with pHLM plus pHLC showed similar results, which indicated that the described metabolites should also be detectable in human urine samples. CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 were identified to be involved in the biotransformation described in this study. An intake of an estimated users' dose of 1 mg/kg BW was detectable via the metabolites by both LC-MS SUSAs for 5-MeO-2-Me-DALT and 5-MeO-2-Me-DIPT. For 5-MeO-2-Me-ALCHT, a separate run using an inclusion list on the targets of interest would be necessary for detection. In addition, 5-MeO-2-Me-DALT metabolites were also detectable after the lower 0.1 mg/kg BW dosage by both LC-MS SUSAs.
